North China Pharmaceutical Group Co. , Ltd. , as of the end of 2018, China Pharmaceutical Group's total assets of 20.6 billion yuan, nearly 15,000 employees, with more than 40 subsidiary companies, it has three national innovation platforms: the National Engineering Research Center for Microbial Drugs, the State Key Laboratory for antibody drug development, and the state local joint engineering laboratory for antibiotic enzyme catalysis and crystallization technology, the main products involve nearly 1,000 product regulations in the fields of chemical pharmacy, modern biotechnology medicine, vitamin and nutrition health care products, modern Chinese medicine, biological pesticide and veterinary drug, etc. , the therapeutic fields include anti-infection, cardio-cerebrovascular, nephrosis, anti-tumor and immunomodulatory, etc. , the process route and production layout of the main production units are all designed and implemented according to the current European and n GMP standards and the new Chinese GMP standards.